Oral small molecule GLP-1 receptor agonist
Orforglipron 24 mg oral once daily
ORFO_PO_24MG_QD
Related
- All doses pooled: Orforglipron tablet
- Orforglipron 12 mg oral once daily
- Orforglipron 36 mg oral once daily
- Orforglipron 6 mg oral once daily
- Orforglipron 3 mg oral once daily
- Orforglipron maximum tolerated dose tablet once daily
- Orforglipron 1 mg tablet once daily
- Orforglipron 14.5 mg tablet once daily
- Orforglipron 17.2 mg tablet once daily
- Orforglipron 0.8 mg tablet once daily
- Orforglipron 2.5 mg tablet once daily
- Orforglipron 5.5 mg tablet once daily
- Orforglipron 9 mg tablet once daily
- Orforglipron 45 mg oral once daily
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 5.57 (0.18 to 191) | 0.24 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -1.87 (-6.90 to 3.21) | 0.38 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 3.04 (0.92 to 8.65) | 0.15 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.73 (1.99 to 6.84) | 0.36 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 7.57 (3.56 to 15.37) | 0.19 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.01 (0.86 to 4.28) | 0.40 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.53 (1.43 to 7.93) | 0.22 |
| Type 2 diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 0.65 (0.01 to 51.05) | 0.56 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.83 (0.05 to 14.22) | 0.48 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -4.30 (-14.32 to 7.64) | 0.52 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -8.23 (-15.32 to 0.19) | 0.52 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.70 (0.22 to 9.72) | 0.41 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.63 (3.20 to 10.00) | 0.27 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 8.38 (3.64 to 18.44) | 0.25 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 5.41 (2.34 to 11.81) | 0.12 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 4.50 (1.81 to 10.76) | 0.19 |
Trials
- NCT05086445A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus2021 · 62 randomized · 12 weeks
- NCT05048719A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus2021 · 383 randomized · 26 weeks
- NCT05051579A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities2021 · 272 randomized · 36 weeks